DYRK1B-STAT3は,ミトコンドリアのバイオエナジェティクスを損なうことで,心臓の縮小と心不全を引き起こします
Lingfang Zhuang1,2, Kangni Jia1,2, Chen Chen1,3
1Department of Cardiovascular Medicine (L.Z., K..J., Z.L., J.Z., J.H., H.Z., Q.F., C.H., H.X., L.L., W.S., R.Z., K.C., X.Y.), Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Circulation
|March 2, 2022
まとめ
双重特異性チロシン調節キナーゼ1B (DYRK1B) はミトコンドリア機能を損なうことで心不全を促進します. DYRK1BまたはSTAT3を阻害すると,心不全モデルにおける心臓の機能とミトコンドリアのバイオエネルギーが改善されます.
科学分野:
- 心臓病科
- 分子生物学
- ミトコンドリア生物学
背景:
- 心不全は世界的な健康問題です
- ミトコンドリア機能障害は心不全の進行に関与しているが,そのメカニズムは不明である.
- キナゼはミトコンドリアの機能に影響を与え,DYRK1Bの調査を促す.
研究 の 目的:
- DYRK1Bがミトコンドリアのバイオエネルギー,心筋縮,心不全における役割を調査する.
- DYRK1Bが心臓機能に影響を与えるメカニズムを解明する.
主な方法:
- 遺伝子組み換えDYRK1Bと ノックアウトマウス
- 横軸大動脈収縮をインビボ心筋縮モデルで利用した.
- RNAシーケンシングとミトコンドリア機能分析を行った.
主要な成果:
- DYRK1Bは衰弱したヒトと肥大したネズミの心臓で上位調節された.
- DYRK1Bの過剰発現は心臓機能障害と線維症を引き起こした.
- DYRK1Bの消去は,STAT3/PGC- 1α経路によるミトコンドリアのバイオエネルギー回復により,心臓の過剰成長と心不全を緩和した.
結論:
- DYRK1Bはミトコンドリア機能障害,心筋縮,心不全において重要な役割を果たします.
- DYRK1Bの阻害は,心不全の潜在的な治療戦略を提供します.
- DYRK1BまたはSTAT3をターゲットにすることで,ミトコンドリア機能を若返らせることで心臓のパフォーマンスを改善できます.
関連する概念動画
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
78
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
78
01:29Heart Failure II: Pathophysiology
85
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
85
01:30Cardiomyopathy II: Dilated Cardiomyopathy
47
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
47
01:22PI3K/mTOR/AKT Signaling Pathway
4.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.1K
01:27Heart Failure I: Introduction
98
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
98
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
77
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
77